Home/Filings/4/0001193125-26-003027
4//SEC Filing

Wallace Eli M. 4

Accession 0001193125-26-003027

CIK 0001869105other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 7:22 PM ET

Size

5.6 KB

Accession

0001193125-26-003027

Insider Transaction Report

Form 4
Period: 2026-01-01
Wallace Eli M.
DirectorChief Executive Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2026-01-01+1,114,4001,114,400 total
    Exercise: $12.52Exp: 2035-12-31Common Stock (1,114,400 underlying)
Footnotes (1)
  • [F1]69,650 of the shares underlying the option vested on January 2, 2026. Thereafter, 1/48th of the shares underlying the option will vest monthly, with full vesting scheduled for October 2, 2029, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.

Documents

1 file

Issuer

BridgeBio Oncology Therapeutics, Inc.

CIK 0001869105

Entity typeother

Related Parties

1
  • filerCIK 0001776352

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 7:22 PM ET
Size
5.6 KB